So what’s hold­ing back Pfiz­er and Gilead from the re­al­ly big M&A deals we’ve all been wait­ing for?

Ja­mi Ru­bin, Gold­man Sachs

Ja­mi Ru­bin at Gold­man Sachs doesn’t mess around. So when her turn came to ask Pfiz­er CEO Ian Read a ques­tion dur­ing the Q1 call with an­a­lysts, she was her typ­i­cal­ly blunt self.

Ru­bin: You and the se­nior man­age­ment team have for some time now been sig­nal­ing a de­sire to go big­ger, do­ing a larg­er-scale trans­ac­tion, and I’m just cu­ri­ous to know what’s hold­ing you back. It’s now May 2, not that I’m im­pa­tient, but is it cor­po­rate tax re­form? Is it some­thing else? Can you re­mind us what you’re look­ing for ex­act­ly, and what are the trig­ger points for mak­ing you de­cide to pull the trig­ger?

Ian Read, Pfiz­er CEO

Read: From a macro stand­point, Ja­mi, I be­lieve the in­dus­try will con­tin­ue to con­sol­i­date over time. I be­lieve there is sim­ply too much re­dun­dan­cy and frag­men­ta­tion, both glob­al­ly and in the U.S., for the sec­tor to con­tin­u­al­ly ef­fi­cient­ly de­liv­er med­i­cines to so­ci­ety. Pfiz­er has been, and I ex­pect will con­tin­ue to be, ac­tive in­dus­try con­sol­ida­tors. How­ev­er, there is a lack of clar­i­ty on po­ten­tial tax re­form, health­care poli­cies of the U.S., and un­cer­tain­ties in the Eu­ro­pean mar­kets both with the French elec­tion and the U.K. snap elec­tion. And on top of that, cer­tain large com­pa­nies have sig­nif­i­cant, al­most bi­na­ry, risks em­bed­ded with­in their busi­ness and pipelines, which could mean­ing­ful­ly al­ter their val­ues.

So we re­main pru­dent in our eval­u­a­tion process re­gard­less of tar­get size. We will con­tin­ue to eval­u­ate deals. We nev­er say nev­er, but I be­lieve the cur­rent en­vi­ron­ment needs to sta­bi­lize in or­der to be an ad­van­ta­geous mar­ket for big deals.

It prob­a­bly didn’t help that Pfiz­er had to start out its call ex­plain­ing that its last big ac­qui­si­tion, the $14 bil­lion Medi­va­tion buy­out, net­ted a prod­uct — Xtan­di — that is ex­pe­ri­enc­ing de­clin­ing sales. That’s not what Pfiz­er, or its in­vestors, had fig­ured on when Read de­ployed the biggest M&A check­ing ac­count in the in­dus­try.

Then last night it was John Mil­li­gan’s turn to talk about Gilead, which has been ad­vised and scold­ed for not putting its big re­serves to work as its hep C for­tunes con­tin­ue to slide at a dra­mat­ic pace.

That talk about tax re­form? Mil­li­gan isn’t lis­ten­ing.

John Mil­li­gan, Gilead CEO

Mil­li­gan: So first of all, with re­gard to Wash­ing­ton, I think that un­cer­tain­ty in Wash­ing­ton seems to be the norm in my 27 years here. So I think we’ve kind of learned to fil­ter that out and fo­cus on the things that are right for the com­pa­ny. There may be tax re­form. There may be repa­tri­a­tion, but you can’t count on it and you can’t wait for it ei­ther.

So we’ve fo­cused our ef­forts — I’ll turn to what you asked last, which is we re­al­ly fo­cused our ef­forts on broad­en­ing our team, adding some depth both sci­en­tif­i­cal­ly and with busi­ness de­vel­op­ment ex­pe­ri­ence so that we in fact have much, much greater ca­pac­i­ty to as­sess things and are in fact ful­ly en­gaged with our teams as­sess­ing a num­ber of dif­fer­ent op­por­tu­ni­ties, which we think could play out over the com­ing year as we start to make progress in get­ting part­ner­ships and po­ten­tial ac­qui­si­tions to­geth­er. So we’re go­ing to just fo­cus on what’s right for Gilead, try to ig­nore the noise glob­al­ly on terms of tax re­form, and do the best thing for the com­pa­ny and for the share­hold­ers in the long term. And we re­al­ly have a great team right now.

Mil­li­gan went on to pro­vide some in­sights in­to what it’s af­ter.

Mil­li­gan: With re­gard to fu­ture legs of stool, I think it’s pret­ty clear we’re look­ing for an­oth­er av­enue to in­crease our op­por­tu­ni­ty for rev­enue, and al­so for help­ing pa­tients with the con­sid­er­able heft that we have, and it’s clear we’ve been fo­cus­ing on on­col­o­gy, where the ques­tion is there in the area, where we can use our re­sources to ac­cel­er­ate prod­ucts to mar­ket and build a mean­ing­ful fran­chise in on­col­o­gy. And that was the hir­ing of Alessan­dro Ri­va; that was the for­ay we made with our busi­ness de­vel­op­ment peo­ple to broad­en and then to look at oth­er things that can build this.

And so I feel very good that we’ve got a num­ber of dif­fer­ent ways to ac­cel­er­ate growth for the com­pa­ny in­to the fu­ture so that a decade from now we’re a very dif­fer­ent com­pa­ny, hav­ing rein­vent­ed our­selves be­yond an­tivi­rals in­to a re­al­ly mul­ti-ther­a­peu­tic area com­pa­ny.

So there you have it. Two big com­pa­nies with plen­ty of fi­nan­cial fire­pow­er and a de­sire to do some­thing im­pres­sive — when the time is ripe. Pfiz­er’s Read is known as the last big megamerg­er play­er while Gilead ac­tu­al­ly turned its ac­qui­si­tion of Phar­mas­set in­to a block­buster — al­though a block­buster that’s cur­ing pa­tients faster than they can di­ag­nose new cas­es.

Every­thing is on the ta­ble right now, from Bris­tol-My­ers Squibb to the lat­est up­start biotech with new tech. But what­ev­er the rea­son, sev­er­al of the big play­ers are still not re­al­ly in the game. And Roche, Sanofi and oth­ers are clear­ly turned off by high val­u­a­tions. It’s a sell­er’s mar­ket right now, and deals aren’t as eas­i­ly come by as every­one ex­pect­ed so far this year.

Biogen CEO Michel Vounatsos (via Getty Images)

With ad­u­canum­ab caught on a cliff, Bio­gen’s Michel Vounatsos bets bil­lions on an­oth­er high-risk neu­ro play

With its FDA pitch on the Alzheimer’s drug aducanumab hanging perilously close to disaster, Biogen is rolling the dice on a $3.1 billion deal that brings in commercial rights to one of the other spotlight neuro drugs in late-stage development — after it already failed its first Phase III.

The big biotech has turned to Sage Therapeutics for its latest deal, close to a year after the crushing failure of Sage-217, now dubbed zuranolone, in the MOUNTAIN study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

Roger Perlmutter is spending his last days at Merck, well, spending.

Two weeks after snapping up the antibody-drug conjugate biotech VelosBio for $2.75 billion, Merck announced today that it had purchased OncoImmune and its experimental Covid-19 drug for $425 million. The drug, known as CD24Fc, appeared to reduce the risk of respiratory failure or death in severe Covid-19 patients by 50% in a 203-person Phase III trial, OncoImmune said in September.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

Af­ter Ko­dak de­ba­cle, US lends $1.1B to a syn­thet­ic bi­ol­o­gy com­pa­ny and their big Covid-19, mR­NA plans

In mid-August, as Kodak’s $765 million government-backed push into drug manufacturing slowly fell apart in national headlines, Ginkgo Bioworks CEO Jason Kelly got a message from his company’s government liaison: HHS wanted to know if they, too, might want a loan.

The government’s decision to lend Kodak three quarters of a billion dollars raised eyebrows because Kodak had never made drugs before. But Ginkgo, while not a manufacturing company, had spent the last decade refining new ways to produce materials inside cells and building automated facilities across Boston.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

Eighteen days ago, virtually all of the outside experts on an FDA adcomm got together to mug the agency’s Billy Dunn and the Biogen team when they presented their upbeat assessment on aducanumab. But here we are, more than 2 weeks later, and the ongoing debate over that Alzheimer’s drug’s fate continues unabated.

Instead of simply ruling out any chance of an approval, the logical conclusion based on what we heard during that session, a series of questionable approvals that preceded the controversy over the agency’s recent EUA decisions has come back to haunt the FDA, where the power of precedent is leaving an opening some experts believe can still be exploited by the big biotech.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)

UP­DAT­ED: Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

Score another early win at the FDA for Alnylam.

The FDA put out word today that the agency has approved its third drug, lumasiran, for primary hyperoxaluria type 1, better known as PH1. The news comes just 4 days after the European Commission took the lead in offering a green light.

An ultra rare genetic condition, Alnylam CEO John Maraganore says there are only some 1,000 to 1,700 patients in the US and Europe at any particular point. The patients, mostly kids, suffer from an overproduction of oxalate in the liver that spurs the development of kidney stones, right through to end stage kidney disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

Bob Nelsen (Photo by Michael Kovac/Getty Images)

Bob Nelsen rais­es $800M and re­cruits a star-stud­ded board to build the 'Fox­con­n' of biotech

Bob Nelsen spent his pandemic spring in his Seattle home, talking on the phone with Luciana Borio, the scientist who used to run pandemic preparedness on the National Security Council, and fuming with her about the dire state of American manufacturing.

Companies were rushing to develop vaccines and antibodies for the new virus, but even if they succeeded, there was no immediate supply chain or infrastructure to mass-produce them in a way that could make a dent in the outbreak.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

Ramy Farid, Schrödinger CEO (Schrödinger)

Bris­tol My­ers fronts new Schrödinger al­liance with $55M up­front, ex­pand­ing pre­ci­sion on­col­o­gy pro­file

Bristol Myers Squibb has a new R&D partner, one to which they’re paying a pretty penny to use their discovery platform.

The pharma company is doling out $55 million upfront to Schrödinger $SDGR to work on up to five small molecules, with the potential for $2.7 billion in milestone payments. Schrödinger’s initial targets include HIF-2 alpha and SOS1/KRAS for a type of kidney cancer and KRAS-driven cancers, respectively.

Carl Hansen, AbCellera CEO (University of British Columbia)

From a pair of Air Jor­dans to a $200M-plus IPO, Carl Hansen is craft­ing an overnight R&D for­tune fu­eled by Covid-19

Back in the summer of 2019, Carl Hansen left his post as a professor at the University of British Columbia to go full time as the CEO at a low-profile antibody shop he had founded called AbCellera.

As biotech CEOs go, even after a fundraise Hansen wasn’t paid a whole heck of a lot. He ended up earning right at $250,000 for the year. His compensation package included a loan — which he later paid back — and a pair of Air Jordan tennis shoes. His newly-hired CFO, Andrew Booth, got a sweeter pay packet than that — which included his own pair of Air Jordans.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.